## FORM 5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvaoriirigiori,	D.O.	200-0

# ANNUAL STATEMENT OF CHANGES IN BENEFICIAL **OWNERSHIP**

OMB APPROVAL								
OMB Number:	3235-0362							
Estimated average burden								
hours per response:	1.0							

Form 3 Holdings Reported.

X Form 4	1 Transactions	Reported.	FI	led pursuant i or Sectio					rities Excha Company Ac										
1. Name and Address of Reporting Person* <u>Kanes Stephen</u>					2. Issuer Name <b>and</b> Ticker or Trading Symbol Sage Therapeutics, Inc. [ SAGE ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner								
(Last) (First) (Middle) C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET					3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2014								X Officer (give title below) Other (specify below)  Chief Medical Officer						
(Street)  CAMBRIDGE MA 02142				4. If Ame	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																
		Tab	le I - Non-Deri	vative Sec	curit	ies Ac	quire	d, Di	sposed	of, or	Benef	iciall	y Owned	l					
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Year			2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transa Code ( 8)	action	4. Securities Acquired (A) or Dispose (D) (Instr. 3, 4 and 5)				sed Of	5. Amount of Securities Beneficially Owned at end		Ownership Form: Direc					
			(WOTHIT/Day)	(Month/Day/Year)			Amour	nt	(A) or D) Price			Issuer's Fi Year (Instr 4)	iscal Ìndire		ect (I)   (Inst				
Common Stock 08/28/2014				M4		[4	60	60,186		\$0.45		63,1	,186		D				
Common	Stock		08/28/2014			M	[4	1,	,162	A	\$1.	36	64,348 D						
		1	able II - Deriva (e.g.,	ative Secu puts, calls									Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	cise (Month/Day/Year) if any (Month/Day/Year)   Code (Instr.   Derivative Securities   Code (Instr.   Code (Ins		7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		Ownership Form: Direct (D)		11. Nature of Indirect Beneficial Ownership (Instr. 4)							
					(A)	(D)	Date Exercis	sable	Expiration Date	Title	or Nu of	nount mber ares							
Stock Option (right to buy)	\$0.45	08/28/2014		4M		60,186	(1)	)	07/18/2023	Comn		,186	\$0.00	162,	036	D			
Stock Option (right to	\$1.36	08/28/2014		4M		1,162	(2)	)	01/01/2024	Comn		162	\$0.00	6,7	74	D			

#### **Explanation of Responses:**

- 1. The option, representing a right to purchase a total of 222,222 shares, became partially exercisable beginning on July 18, 2014. 25% of this option vested on July 18, 2014 and the remainder vests in equal monthly installments thereafter over 36 months.
- 2. The option, representing a right to purchase a total of 7,936 shares, vests in equal monthly installments over 48 months beginning on January 1, 2014.

### Remarks:

/s/ Stephen Kanes

01/26/2015

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.